BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors

Reuters03-15

March 14 (Reuters) - Unicycive Therapeutics Inc

* UNICYCIVE THERAPEUTICS INC: ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN ACCREDITED INVESTORS

* UNICYCIVE THERAPEUTICS: PURSUANT TO AGREEMENT CO AGREED TO ISSUE & SELL, IN PRIVATE PLACEMENT 50,000 SHARES OF ITS SERIES B CONVERTIBLE PREFERRED STOCK

* UNICYCIVE THERAPEUTICS INC: PURCHASE PRICE OF $1,000 PER SHARE WITH AN INITIAL CONVERSION PRICE OF $1.00 PER SHARE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2419795859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-15 04:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2419795859","market":"us","top_or_hot":-1,"title":"BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors","media":"Reuters","content":"<html><body><p>March 14 (Reuters) - Unicycive Therapeutics Inc</p><p> :</p><p>   * UNICYCIVE THERAPEUTICS INC:  ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN ACCREDITED INVESTORS</p><p>   * UNICYCIVE THERAPEUTICS: PURSUANT TO AGREEMENT CO AGREED TO ISSUE &amp; SELL, IN  PRIVATE PLACEMENT 50,000 SHARES OF ITS SERIES B CONVERTIBLE PREFERRED STOCK</p><p>   * UNICYCIVE THERAPEUTICS INC: PURCHASE PRICE OF $1,000 PER SHARE WITH AN INITIAL CONVERSION PRICE OF $1.00 PER SHARE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Unicycive Therapeutics Inc Entered Into A Securities Purchase Agreement With Certain Accredited Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-15 04:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 14 (Reuters) - Unicycive Therapeutics Inc :   * UNICYCIVE THERAPEUTICS INC:  ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN ACCREDITED INVESTORS   * UNICYCIVE THERAPEUTICS: PURSUANT ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISBC","symbol_name":"投资者银行","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2419795859","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2419795859","pubTimestamp":1710448943,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 14  - Unicycive Therapeutics Inc :   * UNICYCIVE THERAPEUTICS INC:  ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN ACCREDITED INVESTORS   * UNICYCIVE THERAPEUTICS: PURSUANT TO AGREEMENT CO AGREED TO ISSUE & SELL, IN  PRIVATE PLACEMENT 50,000 SHARES OF ITS SERIES B CONVERTIBLE PREFERRED STOCK   * UNICYCIVE THERAPEUTICS INC: PURCHASE PRICE OF $1,000 PER SHARE WITH AN INITIAL CONVERSION PRICE OF $1.00 PER SHARESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISBC":"投资者银行","UNCY":"Unicycive Therapeutics, Inc.","BK4139":"生物科技","BK4539":"次新股","BK4211":"区域性银行"},"translate_title":"简介-Unicycive Therapeutics Inc。与若干认可投资者订立证券购买协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1,"UNCY":1},"content_text":"March 14 (Reuters) - Unicycive Therapeutics Inc :   * UNICYCIVE THERAPEUTICS INC:  ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN ACCREDITED INVESTORS   * UNICYCIVE THERAPEUTICS: PURSUANT TO AGREEMENT CO AGREED TO ISSUE & SELL, IN  PRIVATE PLACEMENT 50,000 SHARES OF ITS SERIES B CONVERTIBLE PREFERRED STOCK   * UNICYCIVE THERAPEUTICS INC: PURCHASE PRICE OF $1,000 PER SHARE WITH AN INITIAL CONVERSION PRICE OF $1.00 PER SHARESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2419795859"}